Intellia Therapeutics, Inc.
NTLACIK 0001652130 · last filing Jul 6, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
0 bought / 7,318 sold
net −7,318 sh · −$128.5K
- buys
- 0
- sells
- 2
- insiders active
- 2
Filing tape
Filed Mon, Jul 6, 2026
- −2,641 sh · $44.3K
Dube Michael P — VP, Chief Accounting Officer
- Sold2,641Common Stock@ $16.78→ 66,886 held
- −4,677 sh · $84.2K
Dulac Edward J III — EVP, Chief Financial Officer
- Sold4,677Common Stock@ $18.00→ 156,286 held
Insiders on this tape
- Dube Michael PVP, Chief Accounting Officer
- Dulac Edward J IIIEVP, Chief Financial Officer
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.